On Thursday, the Trump Administration announced agreements with pharmaceutical manufacturers Eli Lilly and Novo Nordisk to reduce the prices for GLP-1 drugs
A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
Theoretically, BPC-157 shows faster onset (4-6 days in animal models vs 2-6 weeks for human SSRIs), multi-system modulation rather than single-target effects, actual neuronal repair and regeneration (neuroprotection), no withdrawal syndrome in animals, and efficacy when given peripherally without extensive blood-brain barrier crossing
When thyroid function is compromised, your body also retains more water and may shift toward storing fat preferentially, especially in the abdomen and face
Deze mensen hebben vaak ook problemen met hun bloedsuiker
The other two are comparative : He chose tirzepatide over pure GLP-1 (semaglutide) based partly on the SURPASS-CVOT trial, which showed tirzepatide performed at least as well as dulaglutide (a GLP-1 agonist) on cardiovascular outcomes, with a post-hoc analysis suggesting a 16% risk reduction on a broader six-component endpoint
.webp)
